Etomidate, a potent intravenous sedative-hypnotic agent, is a cornerstone medication for the rapid induction of general anesthesia. Valued for its hemodynamic stability, rapid onset, and favorable recovery profile, it is extensively used in operating rooms, emergency departments, and intensive care settings worldwide. The global etomidate market, valued at approximately USD 2.3 billion in 2023, is projected to reach USD 3.2 billion by 2033, growing at a steady CAGR of 3.6% . This growth is driven by rising surgical volumes, expanding healthcare infrastructure, and the drug’s established safety profile. Understanding the global buyer landscape is crucial for suppliers, distributors, and stakeholders navigating this specialized pharmaceutical segment. This article provides a detailed…